STAT news have put together a great article assessing the need for health care systems to get on top of the payment issue quickly. Give it a read!
Genomics has the potential to significantly improve the efficacy of drugs and develop targeted therapies.
The Novartis CAR-T cell therapy, Kymriah (tisagenlecleucel), will be made available to patients under the age of 25 via the Cancer Drugs Fund.
If you’ve been part of the GeoMx DSP Technology Access Program, then you’ll already know why this is so exciting. If you haven’t heard about it yet, then you should make sure you’re sitting down – yes it really is that exciting.
The Science and Science Careers’ 2018 annual Top Employers Survey polled employees in the biotechnology, biopharmaceutical, pharmaceutical, and related industries to determine the 20 best employers in these industries as well as their driving characteristics.
Independent US Food and Drug Administration (FDA) advisors unanimously backed Celltrion’s new Rituxan biosimilar recently, potentially allowing the company to threaten the sales dominance of Roche’s top drug.
ASCO checkpoint inhibitor battle between Merck and Roche highlights the pitfalls in directly comparing clinical trial results in the era of precision medicine.
Precision medicine is showing significant signs of success across tumour types.
A type of enzyme called matrix metalloproteinase could be key to the development of “smart” cancer drugs, according to new research.
A team of tiny molecules that work together to make cancer cells less aggressive has been discovered by Australian researchers.
Researchers at the Weizmann Institute of Science, in collaboration with physicians, have conducted a study in mice, in which they used existing drugs in a new combination to help crush potential resistance to treatment.